Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trastuzumab emtansine - Zydus Cadila

Next Previous
Drug Profile

Trastuzumab emtansine - Zydus Cadila

Alternative Names: Ujvira; ZRC-3256

Latest Information Update: 26 May 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Zydus Cadila
  • Class Antineoplastics; Drug conjugates; Immunotoxins; Macrolides; Maytansinoids; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed HER2 positive breast cancer

Most Recent Events

  • 24 May 2021 Launched for HER2-positive-breast cancer in India (IV)
  • 23 Jun 2020 Zydus Cadila completes a phase III trial in HER2-positive-breast cancer (Metastatic disease, Second-line therapy or greater) in India before June 2020 (IV) (CTRI/2018/07/014881)
  • 25 Jul 2019 Zydus Cadila plans a phase III trial in Breast cancer (Metastatic disease, Late-stage disease) in India (CTRI2018-07-014881)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top